SAB Biotherapeutics, Inc. - Laporan Laba Rugi (TTM)

SAB Biotherapeutics, Inc.

Laporan Laba Rugi (TTM)

Laporan Laba Rugi SAB Biotherapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 55 66 78 76 61 56 44 33 24 13 6 4 2 3 3 2 1 0 0
Change (%) 19.77 18.44 -3.56 -19.45 -8.42 -21.27 -25.27 -27.12 -46.95 -49.40 -36.19 -45.32 16.23 6.83 -45.59 -12.58 -71.43 -69.64
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 28 37 52 74 57 58 48 40 1 -8 23 19 17 20 23 27 30 30 30
Change (%) 32.21 40.36 43.74 -23.19 0.95 -17.43 -16.19 -97.85 -1,025.11 -386.07 -14.69 -14.68 21.86 14.71 16.51 12.47 -1.62 1.25
% of Revenue 50.52 55.77 66.09 98.51 93.93 103.54 108.60 121.79 3.59 -62.54 353.56 472.68 737.61 773.32 830.42 1,778.08 2,287.62 7,877.23 26,274.56
Gross Operating Profit 27 29 27 1 4 -2 -4 -7 23 21 -16 -15 -14 -18 -20 -25 -29 -29 -30
Change (%) 7.06 -9.19 -95.75 227.16 -153.47 91.11 89.40 -422.48 -10.56 -178.94 -6.21 -6.45 22.74 15.88 25.01 13.96 1.58 2.17
% of Revenue 49.48 44.23 33.91 1.49 6.07 -3.54 -8.60 -21.79 96.41 162.54 -253.56 -372.68 -637.61 -673.32 -730.42 -1,678.08 -2,187.62 -7,777.23 -26,174.56
SG&A 7 9 10 10 17 19 21 21 16 15 13 12 24 25 25 26 14 13 12
Change (%) 31.41 13.42 -0.70 70.46 10.85 9.88 2.13 -22.92 -10.61 -9.36 -11.10 101.68 3.12 3.84 3.56 -47.02 -7.68 -8.57
% of Revenue 12.26 13.45 12.88 13.26 28.07 33.97 47.41 64.80 68.54 115.47 206.86 288.18 1,062.95 942.99 916.62 1,744.59 1,057.26 3,416.02 10,288.47
R&D -11 36 36
Change (%) 0.00
% of Revenue -15.12 148.85 280.56
OpEx 35 46 62 73 74 77 68 61 53 42 36 31 40 45 49 53 44 43 42
Change (%) 32.06 35.12 18.02 1.68 3.23 -10.68 -10.62 -13.69 -19.93 -14.97 -13.37 29.39 10.80 8.74 9.72 -16.99 -3.53 -1.72
% of Revenue 62.78 69.23 78.97 96.65 122.00 137.51 156.01 186.59 220.97 333.49 560.42 760.87 1,800.56 1,716.31 1,747.04 3,522.67 3,344.87 11,293.25 36,563.04
Operating Income 21 20 16 3 -13 -21 -25 -28 -29 -30 -30 -27 -38 -42 -46 -52 -43 -42 -42
Change (%) -0.96 -19.08 -84.62 -628.57 56.16 17.55 15.53 1.82 2.40 -0.22 -8.41 40.70 10.48 8.86 13.07 -17.12 -1.44 -1.11
% of Revenue 37.22 30.77 21.03 3.35 -22.00 -37.51 -56.01 -86.59 -120.97 -233.49 -460.42 -660.87 -1,700.56 -1,616.31 -1,647.04 -3,422.67 -3,244.87 -11,193.25 -36,463.03
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) -15.25 -18.18 14.21 -20.75 -1.08 -1.10 -2.75 7.65 6.75 1.27 -0.28 -3.02 -5.08 5.95 2.63 -2.15 -2.14 -9.23
% of Revenue -0.85 -0.60 -0.42 -0.49 -0.48 -0.52 -0.66 -0.85 -1.26 -2.54 -5.08 -7.94 -14.08 -11.50 -11.41 -21.51 -24.08 -82.47 -246.58
Net Income 20 21 17 3 -17 -18 -19 -22 -19 -27 -29 -27 -42 -40 -40 -46 -34 -34 -37
Change (%) 2.67 -18.47 -83.07 -701.22 2.47 10.44 15.54 -16.40 44.50 7.77 -6.76 55.06 -5.52 1.14 13.01 -25.15 0.50 8.11
% of Revenue 36.42 31.22 21.49 3.77 -28.16 -31.51 -44.21 -68.34 -78.40 -213.53 -454.80 -664.53 -1,884.50 -1,531.84 -1,450.33 -3,012.27 -2,579.03 -9,071.77 -32,306.71

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista